NCT05684185View on ClinicalTrials.gov

Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia

CompletedOBSERVATIONAL
Enrollment

215

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

April 1, 2022

Study Completion Date

April 30, 2022

Conditions
Rabies Post-exposure Prophylaxis
Interventions
BIOLOGICAL

Intramuscular (IM) rabies post-exposure prophylaxis

one-site, 0.5 mL at Day 0, D3, D7 and D14

BIOLOGICAL

Intradermal (ID) rabies post-exposure prophylaxis

two-site, 0.1 mL at Day 0, D3 and D7

Trial Locations (1)

Unknown

Institut Pasteur du Cambodge (IPC), Phnom Penh

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

Institut Pasteur du Cambodge

OTHER

NCT05684185 - Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia | Biotech Hunter | Biotech Hunter